nodes	percent_of_prediction	percent_of_DWPC	metapath
Etoposide—Topoisomerase Inhibitors—Epirubicin—urinary bladder cancer	0.172	0.519	CiPCiCtD
Etoposide—Topoisomerase Inhibitors—Doxorubicin—urinary bladder cancer	0.159	0.481	CiPCiCtD
Etoposide—prostate cancer—urinary bladder cancer	0.0869	0.373	CtDrD
Etoposide—muscle cancer—urinary bladder cancer	0.0754	0.323	CtDrD
Etoposide—GSTT1—urinary bladder cancer	0.0743	0.49	CbGaD
Etoposide—testicular cancer—urinary bladder cancer	0.0707	0.303	CtDrD
Etoposide—GSTP1—urinary bladder cancer	0.0587	0.387	CbGaD
Etoposide—TOP2A—Valrubicin—urinary bladder cancer	0.0425	0.214	CbGbCtD
Etoposide—GSTT1—Carboplatin—urinary bladder cancer	0.0195	0.0985	CbGbCtD
Etoposide—PTGS2—urinary bladder cancer	0.0186	0.123	CbGaD
Etoposide—GSTT1—Cisplatin—urinary bladder cancer	0.0167	0.0842	CbGbCtD
Etoposide—GSTP1—Carboplatin—urinary bladder cancer	0.0122	0.0616	CbGbCtD
Etoposide—GSTP1—Cisplatin—urinary bladder cancer	0.0104	0.0526	CbGbCtD
Etoposide—ABCC10—Gemcitabine—urinary bladder cancer	0.0101	0.0509	CbGbCtD
Etoposide—ABCC6—Cisplatin—urinary bladder cancer	0.00958	0.0484	CbGbCtD
Etoposide—TOP2A—Epirubicin—urinary bladder cancer	0.00643	0.0325	CbGbCtD
Etoposide—ABCC6—Doxorubicin—urinary bladder cancer	0.00642	0.0324	CbGbCtD
Etoposide—ABCC3—Fluorouracil—urinary bladder cancer	0.00542	0.0274	CbGbCtD
Etoposide—ABCC10—Doxorubicin—urinary bladder cancer	0.00491	0.0248	CbGbCtD
Etoposide—ABCC10—Methotrexate—urinary bladder cancer	0.00475	0.024	CbGbCtD
Etoposide—ABCC3—Cisplatin—urinary bladder cancer	0.0046	0.0232	CbGbCtD
Etoposide—ABCC1—Epirubicin—urinary bladder cancer	0.00357	0.018	CbGbCtD
Etoposide—TOP2A—Doxorubicin—urinary bladder cancer	0.00342	0.0172	CbGbCtD
Etoposide—ABCB1—Mitomycin—urinary bladder cancer	0.00326	0.0165	CbGbCtD
Etoposide—ABCC3—Doxorubicin—urinary bladder cancer	0.00309	0.0156	CbGbCtD
Etoposide—ABCC3—Methotrexate—urinary bladder cancer	0.00299	0.0151	CbGbCtD
Etoposide—ABCC2—Carboplatin—urinary bladder cancer	0.00245	0.0124	CbGbCtD
Etoposide—ABCG2—Fluorouracil—urinary bladder cancer	0.00223	0.0112	CbGbCtD
Etoposide—ABCG2—Carboplatin—urinary bladder cancer	0.00221	0.0112	CbGbCtD
Etoposide—ABCC2—Cisplatin—urinary bladder cancer	0.00209	0.0106	CbGbCtD
Etoposide—PTGS2—Cisplatin—urinary bladder cancer	0.00207	0.0104	CbGbCtD
Etoposide—ABCC1—Doxorubicin—urinary bladder cancer	0.00189	0.00956	CbGbCtD
Etoposide—ABCG2—Cisplatin—urinary bladder cancer	0.00189	0.00955	CbGbCtD
Etoposide—ABCC1—Methotrexate—urinary bladder cancer	0.00184	0.00926	CbGbCtD
Etoposide—GSTT1—urine—urinary bladder cancer	0.0016	0.0907	CbGeAlD
Etoposide—CYP3A4—Thiotepa—urinary bladder cancer	0.00148	0.00747	CbGbCtD
Etoposide—ABCC2—Doxorubicin—urinary bladder cancer	0.0014	0.00708	CbGbCtD
Etoposide—ABCC2—Methotrexate—urinary bladder cancer	0.00136	0.00686	CbGbCtD
Etoposide—ABCG2—Doxorubicin—urinary bladder cancer	0.00127	0.0064	CbGbCtD
Etoposide—ABCG2—Methotrexate—urinary bladder cancer	0.00123	0.0062	CbGbCtD
Etoposide—CYP2C8—Fluorouracil—urinary bladder cancer	0.00119	0.00599	CbGbCtD
Etoposide—ABCB1—Gemcitabine—urinary bladder cancer	0.000939	0.00474	CbGbCtD
Etoposide—UGT1A1—urine—urinary bladder cancer	0.000937	0.0532	CbGeAlD
Etoposide—CYP1A2—Fluorouracil—urinary bladder cancer	0.000918	0.00463	CbGbCtD
Etoposide—GSTP1—urine—urinary bladder cancer	0.000737	0.0419	CbGeAlD
Etoposide—ABCB1—Cisplatin—urinary bladder cancer	0.000682	0.00344	CbGbCtD
Etoposide—GSTT1—prostate gland—urinary bladder cancer	0.000573	0.0326	CbGeAlD
Etoposide—ABCB1—Doxorubicin—urinary bladder cancer	0.000457	0.00231	CbGbCtD
Etoposide—ABCB1—Methotrexate—urinary bladder cancer	0.000443	0.00223	CbGbCtD
Etoposide—TOP2B—prostate gland—urinary bladder cancer	0.000422	0.024	CbGeAlD
Etoposide—CYP1A2—urine—urinary bladder cancer	0.000415	0.0236	CbGeAlD
Etoposide—GSTT1—renal system—urinary bladder cancer	0.000391	0.0222	CbGeAlD
Etoposide—CYP2E1—urine—urinary bladder cancer	0.000373	0.0212	CbGeAlD
Etoposide—TOP2B—seminal vesicle—urinary bladder cancer	0.000357	0.0203	CbGeAlD
Etoposide—UGT1A1—prostate gland—urinary bladder cancer	0.000336	0.0191	CbGeAlD
Etoposide—ABCC6—renal system—urinary bladder cancer	0.000317	0.018	CbGeAlD
Etoposide—GSTT1—female reproductive system—urinary bladder cancer	0.000313	0.0178	CbGeAlD
Etoposide—TOP2A—prostate gland—urinary bladder cancer	0.000311	0.0176	CbGeAlD
Etoposide—CYP3A4—urine—urinary bladder cancer	0.0003	0.0171	CbGeAlD
Etoposide—TOP2B—smooth muscle tissue—urinary bladder cancer	0.000299	0.017	CbGeAlD
Etoposide—TOP2B—renal system—urinary bladder cancer	0.000288	0.0163	CbGeAlD
Etoposide—TOP2B—urethra—urinary bladder cancer	0.000283	0.0161	CbGeAlD
Etoposide—CYP3A4—Doxorubicin—urinary bladder cancer	0.000274	0.00138	CbGbCtD
Etoposide—ABCC3—prostate gland—urinary bladder cancer	0.000266	0.0151	CbGeAlD
Etoposide—GSTP1—prostate gland—urinary bladder cancer	0.000265	0.015	CbGeAlD
Etoposide—ABCC10—prostate gland—urinary bladder cancer	0.000264	0.015	CbGeAlD
Etoposide—TOP2B—female reproductive system—urinary bladder cancer	0.000231	0.0131	CbGeAlD
Etoposide—UGT1A1—renal system—urinary bladder cancer	0.000229	0.013	CbGeAlD
Etoposide—GSTP1—seminal vesicle—urinary bladder cancer	0.000224	0.0127	CbGeAlD
Etoposide—ABCC10—seminal vesicle—urinary bladder cancer	0.000224	0.0127	CbGeAlD
Etoposide—ABCC2—prostate gland—urinary bladder cancer	0.000212	0.0121	CbGeAlD
Etoposide—TOP2B—vagina—urinary bladder cancer	0.000208	0.0118	CbGeAlD
Etoposide—GSTP1—epithelium—urinary bladder cancer	0.000194	0.011	CbGeAlD
Etoposide—GSTP1—smooth muscle tissue—urinary bladder cancer	0.000187	0.0106	CbGeAlD
Etoposide—ABCC1—prostate gland—urinary bladder cancer	0.000187	0.0106	CbGeAlD
Etoposide—ABCC3—renal system—urinary bladder cancer	0.000181	0.0103	CbGeAlD
Etoposide—GSTP1—renal system—urinary bladder cancer	0.00018	0.0102	CbGeAlD
Etoposide—ABCC10—renal system—urinary bladder cancer	0.00018	0.0102	CbGeAlD
Etoposide—GSTP1—urethra—urinary bladder cancer	0.000177	0.0101	CbGeAlD
Etoposide—ABCC10—urethra—urinary bladder cancer	0.000177	0.0101	CbGeAlD
Etoposide—ABCC1—seminal vesicle—urinary bladder cancer	0.000158	0.00898	CbGeAlD
Etoposide—ABCG2—prostate gland—urinary bladder cancer	0.000155	0.00879	CbGeAlD
Etoposide—TOP2A—vagina—urinary bladder cancer	0.000153	0.00871	CbGeAlD
Etoposide—ABCC3—female reproductive system—urinary bladder cancer	0.000145	0.00824	CbGeAlD
Etoposide—ABCC2—renal system—urinary bladder cancer	0.000145	0.00822	CbGeAlD
Etoposide—GSTP1—female reproductive system—urinary bladder cancer	0.000144	0.0082	CbGeAlD
Etoposide—ABCC10—female reproductive system—urinary bladder cancer	0.000144	0.0082	CbGeAlD
Etoposide—CYP3A5—prostate gland—urinary bladder cancer	0.000144	0.00816	CbGeAlD
Etoposide—TOP2B—lymph node—urinary bladder cancer	0.000135	0.00766	CbGeAlD
Etoposide—CYP2E1—prostate gland—urinary bladder cancer	0.000134	0.00761	CbGeAlD
Etoposide—ABCG2—seminal vesicle—urinary bladder cancer	0.000131	0.00744	CbGeAlD
Etoposide—GSTP1—vagina—urinary bladder cancer	0.000131	0.00742	CbGeAlD
Etoposide—ABCC10—vagina—urinary bladder cancer	0.000131	0.00741	CbGeAlD
Etoposide—PTGS1—prostate gland—urinary bladder cancer	0.000129	0.00733	CbGeAlD
Etoposide—ABCC1—urethra—urinary bladder cancer	0.000125	0.00711	CbGeAlD
Etoposide—PTGS2—prostate gland—urinary bladder cancer	0.000123	0.00701	CbGeAlD
Etoposide—ABCC2—female reproductive system—urinary bladder cancer	0.000116	0.00658	CbGeAlD
Etoposide—CYP2E1—seminal vesicle—urinary bladder cancer	0.000113	0.00644	CbGeAlD
Etoposide—PTGS1—seminal vesicle—urinary bladder cancer	0.000109	0.0062	CbGeAlD
Etoposide—CYP2C8—renal system—urinary bladder cancer	0.000109	0.00616	CbGeAlD
Etoposide—TOP2A—Daunorubicin—Valrubicin—urinary bladder cancer	0.000108	0.15	CbGdCrCtD
Etoposide—TOP2A—Epirubicin—Valrubicin—urinary bladder cancer	0.000108	0.15	CbGdCrCtD
Etoposide—TOP2A—Doxorubicin—Valrubicin—urinary bladder cancer	0.000108	0.15	CbGdCrCtD
Etoposide—TOP2A—Idarubicin—Valrubicin—urinary bladder cancer	0.000108	0.15	CbGdCrCtD
Etoposide—PTGS2—seminal vesicle—urinary bladder cancer	0.000104	0.00593	CbGeAlD
Etoposide—ABCG2—urethra—urinary bladder cancer	0.000104	0.00589	CbGeAlD
Etoposide—CYP1A2—renal system—urinary bladder cancer	0.000102	0.00577	CbGeAlD
Etoposide—TOP2A—lymph node—urinary bladder cancer	9.92e-05	0.00563	CbGeAlD
Etoposide—CYP3A5—renal system—urinary bladder cancer	9.79e-05	0.00556	CbGeAlD
Etoposide—PTGS1—epithelium—urinary bladder cancer	9.49e-05	0.00539	CbGeAlD
Etoposide—ABCC1—vagina—urinary bladder cancer	9.23e-05	0.00524	CbGeAlD
Etoposide—PTGS1—smooth muscle tissue—urinary bladder cancer	9.14e-05	0.00519	CbGeAlD
Etoposide—CYP2E1—renal system—urinary bladder cancer	9.13e-05	0.00519	CbGeAlD
Etoposide—PTGS2—epithelium—urinary bladder cancer	9.07e-05	0.00515	CbGeAlD
Etoposide—CYP2E1—urethra—urinary bladder cancer	8.97e-05	0.0051	CbGeAlD
Etoposide—PTGS1—renal system—urinary bladder cancer	8.8e-05	0.005	CbGeAlD
Etoposide—PTGS2—smooth muscle tissue—urinary bladder cancer	8.74e-05	0.00496	CbGeAlD
Etoposide—CYP2C8—female reproductive system—urinary bladder cancer	8.69e-05	0.00494	CbGeAlD
Etoposide—ABCC3—lymph node—urinary bladder cancer	8.48e-05	0.00482	CbGeAlD
Etoposide—GSTP1—lymph node—urinary bladder cancer	8.45e-05	0.0048	CbGeAlD
Etoposide—ABCC10—lymph node—urinary bladder cancer	8.44e-05	0.00479	CbGeAlD
Etoposide—PTGS2—renal system—urinary bladder cancer	8.41e-05	0.00478	CbGeAlD
Etoposide—PTGS2—urethra—urinary bladder cancer	8.26e-05	0.00469	CbGeAlD
Etoposide—CYP2C8—vagina—urinary bladder cancer	7.86e-05	0.00446	CbGeAlD
Etoposide—ABCG2—vagina—urinary bladder cancer	7.64e-05	0.00434	CbGeAlD
Etoposide—ABCB1—prostate gland—urinary bladder cancer	7.63e-05	0.00434	CbGeAlD
Etoposide—CYP3A4—renal system—urinary bladder cancer	7.35e-05	0.00417	CbGeAlD
Etoposide—CYP2E1—female reproductive system—urinary bladder cancer	7.32e-05	0.00416	CbGeAlD
Etoposide—CYP3A5—vagina—urinary bladder cancer	7.09e-05	0.00403	CbGeAlD
Etoposide—PTGS1—female reproductive system—urinary bladder cancer	7.05e-05	0.004	CbGeAlD
Etoposide—ABCC2—lymph node—urinary bladder cancer	6.78e-05	0.00385	CbGeAlD
Etoposide—PTGS2—female reproductive system—urinary bladder cancer	6.74e-05	0.00383	CbGeAlD
Etoposide—ABCB1—seminal vesicle—urinary bladder cancer	6.46e-05	0.00367	CbGeAlD
Etoposide—PTGS1—vagina—urinary bladder cancer	6.37e-05	0.00362	CbGeAlD
Etoposide—PTGS2—vagina—urinary bladder cancer	6.09e-05	0.00346	CbGeAlD
Etoposide—ABCC1—lymph node—urinary bladder cancer	5.97e-05	0.00339	CbGeAlD
Etoposide—CYP3A4—female reproductive system—urinary bladder cancer	5.89e-05	0.00334	CbGeAlD
Etoposide—ABCB1—epithelium—urinary bladder cancer	5.61e-05	0.00319	CbGeAlD
Etoposide—ABCB1—renal system—urinary bladder cancer	5.2e-05	0.00296	CbGeAlD
Etoposide—ABCB1—urethra—urinary bladder cancer	5.11e-05	0.0029	CbGeAlD
Etoposide—ABCG2—lymph node—urinary bladder cancer	4.94e-05	0.00281	CbGeAlD
Etoposide—ABCB1—female reproductive system—urinary bladder cancer	4.17e-05	0.00237	CbGeAlD
Etoposide—PTGS1—lymph node—urinary bladder cancer	4.12e-05	0.00234	CbGeAlD
Etoposide—TOP2A—Cytarabine—Gemcitabine—urinary bladder cancer	4.06e-05	0.0564	CbGdCrCtD
Etoposide—PTGS2—lymph node—urinary bladder cancer	3.94e-05	0.00224	CbGeAlD
Etoposide—ABCB1—vagina—urinary bladder cancer	3.77e-05	0.00214	CbGeAlD
Etoposide—TOP2A—Idarubicin—Epirubicin—urinary bladder cancer	3.76e-05	0.0523	CbGdCrCtD
Etoposide—TOP2A—Doxorubicin—Epirubicin—urinary bladder cancer	3.76e-05	0.0523	CbGdCrCtD
Etoposide—TOP2A—Daunorubicin—Epirubicin—urinary bladder cancer	3.76e-05	0.0523	CbGdCrCtD
Etoposide—TOP2A—Daunorubicin—Doxorubicin—urinary bladder cancer	3.48e-05	0.0484	CbGdCrCtD
Etoposide—TOP2A—Epirubicin—Doxorubicin—urinary bladder cancer	3.48e-05	0.0484	CbGdCrCtD
Etoposide—TOP2A—Idarubicin—Doxorubicin—urinary bladder cancer	3.48e-05	0.0484	CbGdCrCtD
Etoposide—TOP2A—Azacitidine—Gemcitabine—urinary bladder cancer	2.91e-05	0.0404	CbGdCrCtD
Etoposide—Pruritus—Thiotepa—urinary bladder cancer	2.46e-05	0.00061	CcSEcCtD
Etoposide—Pain—Fluorouracil—urinary bladder cancer	2.46e-05	0.00061	CcSEcCtD
Etoposide—Paraesthesia—Cisplatin—urinary bladder cancer	2.45e-05	0.000607	CcSEcCtD
Etoposide—ABCB1—lymph node—urinary bladder cancer	2.44e-05	0.00138	CbGeAlD
Etoposide—Dyspnoea—Cisplatin—urinary bladder cancer	2.43e-05	0.000603	CcSEcCtD
Etoposide—Feeling abnormal—Gemcitabine—urinary bladder cancer	2.41e-05	0.000598	CcSEcCtD
Etoposide—Diarrhoea—Thiotepa—urinary bladder cancer	2.38e-05	0.00059	CcSEcCtD
Etoposide—Toxic epidermal necrolysis—Doxorubicin—urinary bladder cancer	2.38e-05	0.000589	CcSEcCtD
Etoposide—Decreased appetite—Cisplatin—urinary bladder cancer	2.37e-05	0.000588	CcSEcCtD
Etoposide—Feeling abnormal—Fluorouracil—urinary bladder cancer	2.37e-05	0.000588	CcSEcCtD
Etoposide—Pneumonia—Methotrexate—urinary bladder cancer	2.36e-05	0.000585	CcSEcCtD
Etoposide—Gastrointestinal disorder—Cisplatin—urinary bladder cancer	2.36e-05	0.000584	CcSEcCtD
Etoposide—Infestation NOS—Methotrexate—urinary bladder cancer	2.35e-05	0.000582	CcSEcCtD
Etoposide—Infestation—Methotrexate—urinary bladder cancer	2.35e-05	0.000582	CcSEcCtD
Etoposide—Pancytopenia—Epirubicin—urinary bladder cancer	2.34e-05	0.00058	CcSEcCtD
Etoposide—Pain—Cisplatin—urinary bladder cancer	2.33e-05	0.000578	CcSEcCtD
Etoposide—Stevens-Johnson syndrome—Methotrexate—urinary bladder cancer	2.33e-05	0.000577	CcSEcCtD
Etoposide—Alanine aminotransferase increased—Doxorubicin—urinary bladder cancer	2.33e-05	0.000577	CcSEcCtD
Etoposide—Body temperature increased—Gemcitabine—urinary bladder cancer	2.31e-05	0.000573	CcSEcCtD
Etoposide—Renal failure—Methotrexate—urinary bladder cancer	2.31e-05	0.000572	CcSEcCtD
Etoposide—Neutropenia—Epirubicin—urinary bladder cancer	2.3e-05	0.000571	CcSEcCtD
Etoposide—Dizziness—Thiotepa—urinary bladder cancer	2.3e-05	0.00057	CcSEcCtD
Etoposide—Stomatitis—Methotrexate—urinary bladder cancer	2.29e-05	0.000567	CcSEcCtD
Etoposide—Urticaria—Fluorouracil—urinary bladder cancer	2.29e-05	0.000567	CcSEcCtD
Etoposide—Dysphagia—Doxorubicin—urinary bladder cancer	2.28e-05	0.000565	CcSEcCtD
Etoposide—Body temperature increased—Fluorouracil—urinary bladder cancer	2.28e-05	0.000564	CcSEcCtD
Etoposide—Feeling abnormal—Cisplatin—urinary bladder cancer	2.25e-05	0.000557	CcSEcCtD
Etoposide—Hepatobiliary disease—Methotrexate—urinary bladder cancer	2.22e-05	0.00055	CcSEcCtD
Etoposide—Vomiting—Thiotepa—urinary bladder cancer	2.21e-05	0.000548	CcSEcCtD
Etoposide—Pneumonia—Epirubicin—urinary bladder cancer	2.21e-05	0.000548	CcSEcCtD
Etoposide—Infestation NOS—Epirubicin—urinary bladder cancer	2.2e-05	0.000544	CcSEcCtD
Etoposide—Infestation—Epirubicin—urinary bladder cancer	2.2e-05	0.000544	CcSEcCtD
Etoposide—Rash—Thiotepa—urinary bladder cancer	2.19e-05	0.000544	CcSEcCtD
Etoposide—Dermatitis—Thiotepa—urinary bladder cancer	2.19e-05	0.000543	CcSEcCtD
Etoposide—Agranulocytosis—Methotrexate—urinary bladder cancer	2.19e-05	0.000543	CcSEcCtD
Etoposide—Headache—Thiotepa—urinary bladder cancer	2.18e-05	0.00054	CcSEcCtD
Etoposide—Stevens-Johnson syndrome—Epirubicin—urinary bladder cancer	2.18e-05	0.00054	CcSEcCtD
Etoposide—Pancytopenia—Doxorubicin—urinary bladder cancer	2.17e-05	0.000537	CcSEcCtD
Etoposide—Renal failure—Epirubicin—urinary bladder cancer	2.16e-05	0.000535	CcSEcCtD
Etoposide—Body temperature increased—Cisplatin—urinary bladder cancer	2.16e-05	0.000534	CcSEcCtD
Etoposide—Neuropathy peripheral—Epirubicin—urinary bladder cancer	2.15e-05	0.000534	CcSEcCtD
Etoposide—Jaundice—Epirubicin—urinary bladder cancer	2.14e-05	0.000531	CcSEcCtD
Etoposide—Stomatitis—Epirubicin—urinary bladder cancer	2.14e-05	0.000531	CcSEcCtD
Etoposide—Neutropenia—Doxorubicin—urinary bladder cancer	2.13e-05	0.000528	CcSEcCtD
Etoposide—Hypersensitivity—Fluorouracil—urinary bladder cancer	2.12e-05	0.000525	CcSEcCtD
Etoposide—Asthenia—Gemcitabine—urinary bladder cancer	2.1e-05	0.00052	CcSEcCtD
Etoposide—Urinary tract disorder—Methotrexate—urinary bladder cancer	2.08e-05	0.000516	CcSEcCtD
Etoposide—Hepatobiliary disease—Epirubicin—urinary bladder cancer	2.08e-05	0.000515	CcSEcCtD
Etoposide—Pruritus—Gemcitabine—urinary bladder cancer	2.07e-05	0.000513	CcSEcCtD
Etoposide—Nausea—Thiotepa—urinary bladder cancer	2.07e-05	0.000512	CcSEcCtD
Etoposide—Urethral disorder—Methotrexate—urinary bladder cancer	2.07e-05	0.000512	CcSEcCtD
Etoposide—Agranulocytosis—Epirubicin—urinary bladder cancer	2.05e-05	0.000508	CcSEcCtD
Etoposide—Pneumonia—Doxorubicin—urinary bladder cancer	2.05e-05	0.000507	CcSEcCtD
Etoposide—Pruritus—Fluorouracil—urinary bladder cancer	2.04e-05	0.000505	CcSEcCtD
Etoposide—Infestation NOS—Doxorubicin—urinary bladder cancer	2.03e-05	0.000504	CcSEcCtD
Etoposide—Infestation—Doxorubicin—urinary bladder cancer	2.03e-05	0.000504	CcSEcCtD
Etoposide—Stevens-Johnson syndrome—Doxorubicin—urinary bladder cancer	2.02e-05	0.000499	CcSEcCtD
Etoposide—Hypersensitivity—Cisplatin—urinary bladder cancer	2.01e-05	0.000498	CcSEcCtD
Etoposide—Diarrhoea—Gemcitabine—urinary bladder cancer	2e-05	0.000496	CcSEcCtD
Etoposide—Renal failure—Doxorubicin—urinary bladder cancer	2e-05	0.000495	CcSEcCtD
Etoposide—Erythema multiforme—Methotrexate—urinary bladder cancer	1.99e-05	0.000494	CcSEcCtD
Etoposide—Neuropathy peripheral—Doxorubicin—urinary bladder cancer	1.99e-05	0.000494	CcSEcCtD
Etoposide—Stomatitis—Doxorubicin—urinary bladder cancer	1.98e-05	0.000491	CcSEcCtD
Etoposide—Jaundice—Doxorubicin—urinary bladder cancer	1.98e-05	0.000491	CcSEcCtD
Etoposide—Eye disorder—Methotrexate—urinary bladder cancer	1.97e-05	0.000488	CcSEcCtD
Etoposide—Diarrhoea—Fluorouracil—urinary bladder cancer	1.97e-05	0.000488	CcSEcCtD
Etoposide—Hypoaesthesia—Epirubicin—urinary bladder cancer	1.96e-05	0.000486	CcSEcCtD
Etoposide—Asthenia—Cisplatin—urinary bladder cancer	1.96e-05	0.000485	CcSEcCtD
Etoposide—Cardiac disorder—Methotrexate—urinary bladder cancer	1.96e-05	0.000485	CcSEcCtD
Etoposide—Urinary tract disorder—Epirubicin—urinary bladder cancer	1.95e-05	0.000483	CcSEcCtD
Etoposide—Urethral disorder—Epirubicin—urinary bladder cancer	1.93e-05	0.000479	CcSEcCtD
Etoposide—Hepatobiliary disease—Doxorubicin—urinary bladder cancer	1.92e-05	0.000476	CcSEcCtD
Etoposide—Angiopathy—Methotrexate—urinary bladder cancer	1.91e-05	0.000474	CcSEcCtD
Etoposide—Immune system disorder—Methotrexate—urinary bladder cancer	1.9e-05	0.000472	CcSEcCtD
Etoposide—Dizziness—Fluorouracil—urinary bladder cancer	1.9e-05	0.000472	CcSEcCtD
Etoposide—Mediastinal disorder—Methotrexate—urinary bladder cancer	1.9e-05	0.000471	CcSEcCtD
Etoposide—Agranulocytosis—Doxorubicin—urinary bladder cancer	1.9e-05	0.00047	CcSEcCtD
Etoposide—Chills—Methotrexate—urinary bladder cancer	1.89e-05	0.000469	CcSEcCtD
Etoposide—Diarrhoea—Cisplatin—urinary bladder cancer	1.87e-05	0.000463	CcSEcCtD
Etoposide—Erythema multiforme—Epirubicin—urinary bladder cancer	1.87e-05	0.000462	CcSEcCtD
Etoposide—Alopecia—Methotrexate—urinary bladder cancer	1.86e-05	0.000461	CcSEcCtD
Etoposide—Vomiting—Gemcitabine—urinary bladder cancer	1.86e-05	0.000461	CcSEcCtD
Etoposide—Rash—Gemcitabine—urinary bladder cancer	1.85e-05	0.000457	CcSEcCtD
Etoposide—Dermatitis—Gemcitabine—urinary bladder cancer	1.84e-05	0.000457	CcSEcCtD
Etoposide—Eye disorder—Epirubicin—urinary bladder cancer	1.84e-05	0.000457	CcSEcCtD
Etoposide—Headache—Gemcitabine—urinary bladder cancer	1.83e-05	0.000454	CcSEcCtD
Etoposide—Cardiac disorder—Epirubicin—urinary bladder cancer	1.83e-05	0.000454	CcSEcCtD
Etoposide—Flushing—Epirubicin—urinary bladder cancer	1.83e-05	0.000454	CcSEcCtD
Etoposide—Vomiting—Fluorouracil—urinary bladder cancer	1.83e-05	0.000453	CcSEcCtD
Etoposide—Hypoaesthesia—Doxorubicin—urinary bladder cancer	1.82e-05	0.00045	CcSEcCtD
Etoposide—Rash—Fluorouracil—urinary bladder cancer	1.82e-05	0.00045	CcSEcCtD
Etoposide—Dermatitis—Fluorouracil—urinary bladder cancer	1.81e-05	0.000449	CcSEcCtD
Etoposide—Headache—Fluorouracil—urinary bladder cancer	1.8e-05	0.000447	CcSEcCtD
Etoposide—Urinary tract disorder—Doxorubicin—urinary bladder cancer	1.8e-05	0.000447	CcSEcCtD
Etoposide—Dysgeusia—Methotrexate—urinary bladder cancer	1.8e-05	0.000445	CcSEcCtD
Etoposide—Angiopathy—Epirubicin—urinary bladder cancer	1.79e-05	0.000443	CcSEcCtD
Etoposide—Urethral disorder—Doxorubicin—urinary bladder cancer	1.79e-05	0.000443	CcSEcCtD
Etoposide—Immune system disorder—Epirubicin—urinary bladder cancer	1.78e-05	0.000441	CcSEcCtD
Etoposide—Mediastinal disorder—Epirubicin—urinary bladder cancer	1.78e-05	0.00044	CcSEcCtD
Etoposide—Back pain—Methotrexate—urinary bladder cancer	1.78e-05	0.00044	CcSEcCtD
Etoposide—Chills—Epirubicin—urinary bladder cancer	1.77e-05	0.000439	CcSEcCtD
Etoposide—Alopecia—Epirubicin—urinary bladder cancer	1.74e-05	0.000432	CcSEcCtD
Etoposide—Nausea—Gemcitabine—urinary bladder cancer	1.74e-05	0.000431	CcSEcCtD
Etoposide—Vomiting—Cisplatin—urinary bladder cancer	1.74e-05	0.00043	CcSEcCtD
Etoposide—Erythema multiforme—Doxorubicin—urinary bladder cancer	1.73e-05	0.000428	CcSEcCtD
Etoposide—Rash—Cisplatin—urinary bladder cancer	1.72e-05	0.000426	CcSEcCtD
Etoposide—Dermatitis—Cisplatin—urinary bladder cancer	1.72e-05	0.000426	CcSEcCtD
Etoposide—Nausea—Fluorouracil—urinary bladder cancer	1.71e-05	0.000424	CcSEcCtD
Etoposide—Eye disorder—Doxorubicin—urinary bladder cancer	1.71e-05	0.000423	CcSEcCtD
Etoposide—Ill-defined disorder—Methotrexate—urinary bladder cancer	1.7e-05	0.000422	CcSEcCtD
Etoposide—Anaemia—Methotrexate—urinary bladder cancer	1.7e-05	0.00042	CcSEcCtD
Etoposide—Cardiac disorder—Doxorubicin—urinary bladder cancer	1.69e-05	0.00042	CcSEcCtD
Etoposide—Flushing—Doxorubicin—urinary bladder cancer	1.69e-05	0.00042	CcSEcCtD
Etoposide—Dysgeusia—Epirubicin—urinary bladder cancer	1.68e-05	0.000417	CcSEcCtD
Etoposide—Back pain—Epirubicin—urinary bladder cancer	1.66e-05	0.000412	CcSEcCtD
Etoposide—Angiopathy—Doxorubicin—urinary bladder cancer	1.66e-05	0.00041	CcSEcCtD
Etoposide—Malaise—Methotrexate—urinary bladder cancer	1.65e-05	0.00041	CcSEcCtD
Etoposide—Muscle spasms—Epirubicin—urinary bladder cancer	1.65e-05	0.000409	CcSEcCtD
Etoposide—Immune system disorder—Doxorubicin—urinary bladder cancer	1.65e-05	0.000408	CcSEcCtD
Etoposide—Vertigo—Methotrexate—urinary bladder cancer	1.65e-05	0.000408	CcSEcCtD
Etoposide—Mediastinal disorder—Doxorubicin—urinary bladder cancer	1.65e-05	0.000408	CcSEcCtD
Etoposide—Leukopenia—Methotrexate—urinary bladder cancer	1.64e-05	0.000407	CcSEcCtD
Etoposide—Chills—Doxorubicin—urinary bladder cancer	1.64e-05	0.000406	CcSEcCtD
Etoposide—Nausea—Cisplatin—urinary bladder cancer	1.62e-05	0.000402	CcSEcCtD
Etoposide—Alopecia—Doxorubicin—urinary bladder cancer	1.61e-05	0.0004	CcSEcCtD
Etoposide—Cough—Methotrexate—urinary bladder cancer	1.6e-05	0.000397	CcSEcCtD
Etoposide—Ill-defined disorder—Epirubicin—urinary bladder cancer	1.59e-05	0.000395	CcSEcCtD
Etoposide—Convulsion—Methotrexate—urinary bladder cancer	1.59e-05	0.000394	CcSEcCtD
Etoposide—Anaemia—Epirubicin—urinary bladder cancer	1.59e-05	0.000393	CcSEcCtD
Etoposide—Chest pain—Methotrexate—urinary bladder cancer	1.56e-05	0.000387	CcSEcCtD
Etoposide—Dysgeusia—Doxorubicin—urinary bladder cancer	1.56e-05	0.000385	CcSEcCtD
Etoposide—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—urinary bladder cancer	1.55e-05	0.000384	CcSEcCtD
Etoposide—Malaise—Epirubicin—urinary bladder cancer	1.55e-05	0.000384	CcSEcCtD
Etoposide—Discomfort—Methotrexate—urinary bladder cancer	1.54e-05	0.000382	CcSEcCtD
Etoposide—Vertigo—Epirubicin—urinary bladder cancer	1.54e-05	0.000382	CcSEcCtD
Etoposide—Leukopenia—Epirubicin—urinary bladder cancer	1.54e-05	0.000381	CcSEcCtD
Etoposide—Back pain—Doxorubicin—urinary bladder cancer	1.54e-05	0.000381	CcSEcCtD
Etoposide—Muscle spasms—Doxorubicin—urinary bladder cancer	1.53e-05	0.000378	CcSEcCtD
Etoposide—Confusional state—Methotrexate—urinary bladder cancer	1.51e-05	0.000374	CcSEcCtD
Etoposide—Loss of consciousness—Epirubicin—urinary bladder cancer	1.51e-05	0.000374	CcSEcCtD
Etoposide—Cough—Epirubicin—urinary bladder cancer	1.5e-05	0.000371	CcSEcCtD
Etoposide—Anaphylactic shock—Methotrexate—urinary bladder cancer	1.5e-05	0.000371	CcSEcCtD
Etoposide—Convulsion—Epirubicin—urinary bladder cancer	1.49e-05	0.000369	CcSEcCtD
Etoposide—Infection—Methotrexate—urinary bladder cancer	1.49e-05	0.000369	CcSEcCtD
Etoposide—Hypertension—Epirubicin—urinary bladder cancer	1.48e-05	0.000367	CcSEcCtD
Etoposide—Ill-defined disorder—Doxorubicin—urinary bladder cancer	1.47e-05	0.000365	CcSEcCtD
Etoposide—Anaemia—Doxorubicin—urinary bladder cancer	1.47e-05	0.000364	CcSEcCtD
Etoposide—Thrombocytopenia—Methotrexate—urinary bladder cancer	1.47e-05	0.000363	CcSEcCtD
Etoposide—Chest pain—Epirubicin—urinary bladder cancer	1.46e-05	0.000362	CcSEcCtD
Etoposide—Skin disorder—Methotrexate—urinary bladder cancer	1.45e-05	0.00036	CcSEcCtD
Etoposide—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—urinary bladder cancer	1.45e-05	0.00036	CcSEcCtD
Etoposide—Hyperhidrosis—Methotrexate—urinary bladder cancer	1.45e-05	0.000359	CcSEcCtD
Etoposide—Discomfort—Epirubicin—urinary bladder cancer	1.44e-05	0.000358	CcSEcCtD
Etoposide—Malaise—Doxorubicin—urinary bladder cancer	1.43e-05	0.000355	CcSEcCtD
Etoposide—Vertigo—Doxorubicin—urinary bladder cancer	1.43e-05	0.000354	CcSEcCtD
Etoposide—Anorexia—Methotrexate—urinary bladder cancer	1.43e-05	0.000354	CcSEcCtD
Etoposide—Leukopenia—Doxorubicin—urinary bladder cancer	1.42e-05	0.000352	CcSEcCtD
Etoposide—Confusional state—Epirubicin—urinary bladder cancer	1.41e-05	0.00035	CcSEcCtD
Etoposide—Anaphylactic shock—Epirubicin—urinary bladder cancer	1.4e-05	0.000347	CcSEcCtD
Etoposide—Hypotension—Methotrexate—urinary bladder cancer	1.4e-05	0.000347	CcSEcCtD
Etoposide—Loss of consciousness—Doxorubicin—urinary bladder cancer	1.4e-05	0.000346	CcSEcCtD
Etoposide—Infection—Epirubicin—urinary bladder cancer	1.39e-05	0.000345	CcSEcCtD
Etoposide—Cough—Doxorubicin—urinary bladder cancer	1.39e-05	0.000344	CcSEcCtD
Etoposide—Convulsion—Doxorubicin—urinary bladder cancer	1.38e-05	0.000341	CcSEcCtD
Etoposide—Thrombocytopenia—Epirubicin—urinary bladder cancer	1.37e-05	0.00034	CcSEcCtD
Etoposide—Hypertension—Doxorubicin—urinary bladder cancer	1.37e-05	0.00034	CcSEcCtD
Etoposide—Tachycardia—Epirubicin—urinary bladder cancer	1.37e-05	0.000339	CcSEcCtD
Etoposide—Skin disorder—Epirubicin—urinary bladder cancer	1.36e-05	0.000337	CcSEcCtD
Etoposide—Hyperhidrosis—Epirubicin—urinary bladder cancer	1.36e-05	0.000336	CcSEcCtD
Etoposide—Chest pain—Doxorubicin—urinary bladder cancer	1.35e-05	0.000335	CcSEcCtD
Etoposide—Paraesthesia—Methotrexate—urinary bladder cancer	1.34e-05	0.000333	CcSEcCtD
Etoposide—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—urinary bladder cancer	1.34e-05	0.000333	CcSEcCtD
Etoposide—Discomfort—Doxorubicin—urinary bladder cancer	1.34e-05	0.000331	CcSEcCtD
Etoposide—Anorexia—Epirubicin—urinary bladder cancer	1.34e-05	0.000331	CcSEcCtD
Etoposide—Dyspnoea—Methotrexate—urinary bladder cancer	1.34e-05	0.000331	CcSEcCtD
Etoposide—Somnolence—Methotrexate—urinary bladder cancer	1.33e-05	0.00033	CcSEcCtD
Etoposide—Hypotension—Epirubicin—urinary bladder cancer	1.31e-05	0.000324	CcSEcCtD
Etoposide—Confusional state—Doxorubicin—urinary bladder cancer	1.31e-05	0.000324	CcSEcCtD
Etoposide—Decreased appetite—Methotrexate—urinary bladder cancer	1.3e-05	0.000323	CcSEcCtD
Etoposide—Anaphylactic shock—Doxorubicin—urinary bladder cancer	1.3e-05	0.000321	CcSEcCtD
Etoposide—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	1.29e-05	0.00032	CcSEcCtD
Etoposide—Fatigue—Methotrexate—urinary bladder cancer	1.29e-05	0.00032	CcSEcCtD
Etoposide—Infection—Doxorubicin—urinary bladder cancer	1.29e-05	0.000319	CcSEcCtD
Etoposide—Pain—Methotrexate—urinary bladder cancer	1.28e-05	0.000317	CcSEcCtD
Etoposide—Thrombocytopenia—Doxorubicin—urinary bladder cancer	1.27e-05	0.000315	CcSEcCtD
Etoposide—Tachycardia—Doxorubicin—urinary bladder cancer	1.27e-05	0.000314	CcSEcCtD
Etoposide—Skin disorder—Doxorubicin—urinary bladder cancer	1.26e-05	0.000312	CcSEcCtD
Etoposide—Paraesthesia—Epirubicin—urinary bladder cancer	1.26e-05	0.000312	CcSEcCtD
Etoposide—Hyperhidrosis—Doxorubicin—urinary bladder cancer	1.25e-05	0.000311	CcSEcCtD
Etoposide—Dyspnoea—Epirubicin—urinary bladder cancer	1.25e-05	0.00031	CcSEcCtD
Etoposide—Somnolence—Epirubicin—urinary bladder cancer	1.25e-05	0.000309	CcSEcCtD
Etoposide—Anorexia—Doxorubicin—urinary bladder cancer	1.24e-05	0.000306	CcSEcCtD
Etoposide—Feeling abnormal—Methotrexate—urinary bladder cancer	1.23e-05	0.000306	CcSEcCtD
Etoposide—Gastrointestinal pain—Methotrexate—urinary bladder cancer	1.22e-05	0.000303	CcSEcCtD
Etoposide—Decreased appetite—Epirubicin—urinary bladder cancer	1.22e-05	0.000302	CcSEcCtD
Etoposide—Hypotension—Doxorubicin—urinary bladder cancer	1.21e-05	0.0003	CcSEcCtD
Etoposide—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	1.21e-05	0.0003	CcSEcCtD
Etoposide—Fatigue—Epirubicin—urinary bladder cancer	1.21e-05	0.000299	CcSEcCtD
Etoposide—Pain—Epirubicin—urinary bladder cancer	1.2e-05	0.000297	CcSEcCtD
Etoposide—Constipation—Epirubicin—urinary bladder cancer	1.2e-05	0.000297	CcSEcCtD
Etoposide—Urticaria—Methotrexate—urinary bladder cancer	1.19e-05	0.000295	CcSEcCtD
Etoposide—Abdominal pain—Methotrexate—urinary bladder cancer	1.18e-05	0.000293	CcSEcCtD
Etoposide—Body temperature increased—Methotrexate—urinary bladder cancer	1.18e-05	0.000293	CcSEcCtD
Etoposide—Paraesthesia—Doxorubicin—urinary bladder cancer	1.16e-05	0.000288	CcSEcCtD
Etoposide—Dyspnoea—Doxorubicin—urinary bladder cancer	1.16e-05	0.000286	CcSEcCtD
Etoposide—Feeling abnormal—Epirubicin—urinary bladder cancer	1.16e-05	0.000286	CcSEcCtD
Etoposide—Somnolence—Doxorubicin—urinary bladder cancer	1.15e-05	0.000286	CcSEcCtD
Etoposide—Gastrointestinal pain—Epirubicin—urinary bladder cancer	1.15e-05	0.000284	CcSEcCtD
Etoposide—Decreased appetite—Doxorubicin—urinary bladder cancer	1.13e-05	0.000279	CcSEcCtD
Etoposide—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	1.12e-05	0.000277	CcSEcCtD
Etoposide—Fatigue—Doxorubicin—urinary bladder cancer	1.12e-05	0.000277	CcSEcCtD
Etoposide—Urticaria—Epirubicin—urinary bladder cancer	1.11e-05	0.000276	CcSEcCtD
Etoposide—Constipation—Doxorubicin—urinary bladder cancer	1.11e-05	0.000275	CcSEcCtD
Etoposide—Pain—Doxorubicin—urinary bladder cancer	1.11e-05	0.000275	CcSEcCtD
Etoposide—Body temperature increased—Epirubicin—urinary bladder cancer	1.11e-05	0.000274	CcSEcCtD
Etoposide—Abdominal pain—Epirubicin—urinary bladder cancer	1.11e-05	0.000274	CcSEcCtD
Etoposide—Hypersensitivity—Methotrexate—urinary bladder cancer	1.1e-05	0.000273	CcSEcCtD
Etoposide—Asthenia—Methotrexate—urinary bladder cancer	1.07e-05	0.000266	CcSEcCtD
Etoposide—Feeling abnormal—Doxorubicin—urinary bladder cancer	1.07e-05	0.000265	CcSEcCtD
Etoposide—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	1.06e-05	0.000263	CcSEcCtD
Etoposide—Pruritus—Methotrexate—urinary bladder cancer	1.06e-05	0.000262	CcSEcCtD
Etoposide—Hypersensitivity—Epirubicin—urinary bladder cancer	1.03e-05	0.000256	CcSEcCtD
Etoposide—Urticaria—Doxorubicin—urinary bladder cancer	1.03e-05	0.000255	CcSEcCtD
Etoposide—Body temperature increased—Doxorubicin—urinary bladder cancer	1.03e-05	0.000254	CcSEcCtD
Etoposide—Abdominal pain—Doxorubicin—urinary bladder cancer	1.03e-05	0.000254	CcSEcCtD
Etoposide—Diarrhoea—Methotrexate—urinary bladder cancer	1.02e-05	0.000254	CcSEcCtD
Etoposide—Asthenia—Epirubicin—urinary bladder cancer	1.01e-05	0.000249	CcSEcCtD
Etoposide—Pruritus—Epirubicin—urinary bladder cancer	9.92e-06	0.000246	CcSEcCtD
Etoposide—Dizziness—Methotrexate—urinary bladder cancer	9.9e-06	0.000245	CcSEcCtD
Etoposide—Diarrhoea—Epirubicin—urinary bladder cancer	9.59e-06	0.000238	CcSEcCtD
Etoposide—Hypersensitivity—Doxorubicin—urinary bladder cancer	9.56e-06	0.000237	CcSEcCtD
Etoposide—Vomiting—Methotrexate—urinary bladder cancer	9.52e-06	0.000236	CcSEcCtD
Etoposide—Rash—Methotrexate—urinary bladder cancer	9.44e-06	0.000234	CcSEcCtD
Etoposide—Dermatitis—Methotrexate—urinary bladder cancer	9.43e-06	0.000234	CcSEcCtD
Etoposide—Headache—Methotrexate—urinary bladder cancer	9.38e-06	0.000232	CcSEcCtD
Etoposide—Asthenia—Doxorubicin—urinary bladder cancer	9.31e-06	0.000231	CcSEcCtD
Etoposide—Dizziness—Epirubicin—urinary bladder cancer	9.27e-06	0.00023	CcSEcCtD
Etoposide—Pruritus—Doxorubicin—urinary bladder cancer	9.18e-06	0.000227	CcSEcCtD
Etoposide—Vomiting—Epirubicin—urinary bladder cancer	8.91e-06	0.000221	CcSEcCtD
Etoposide—Nausea—Methotrexate—urinary bladder cancer	8.9e-06	0.00022	CcSEcCtD
Etoposide—Diarrhoea—Doxorubicin—urinary bladder cancer	8.87e-06	0.00022	CcSEcCtD
Etoposide—Rash—Epirubicin—urinary bladder cancer	8.84e-06	0.000219	CcSEcCtD
Etoposide—Dermatitis—Epirubicin—urinary bladder cancer	8.83e-06	0.000219	CcSEcCtD
Etoposide—Headache—Epirubicin—urinary bladder cancer	8.78e-06	0.000218	CcSEcCtD
Etoposide—Dizziness—Doxorubicin—urinary bladder cancer	8.58e-06	0.000212	CcSEcCtD
Etoposide—Nausea—Epirubicin—urinary bladder cancer	8.33e-06	0.000206	CcSEcCtD
Etoposide—Vomiting—Doxorubicin—urinary bladder cancer	8.25e-06	0.000204	CcSEcCtD
Etoposide—Rash—Doxorubicin—urinary bladder cancer	8.18e-06	0.000203	CcSEcCtD
Etoposide—Dermatitis—Doxorubicin—urinary bladder cancer	8.17e-06	0.000202	CcSEcCtD
Etoposide—Headache—Doxorubicin—urinary bladder cancer	8.12e-06	0.000201	CcSEcCtD
Etoposide—Nausea—Doxorubicin—urinary bladder cancer	7.7e-06	0.000191	CcSEcCtD
Etoposide—UGT1A1—Metabolism—GSTP1—urinary bladder cancer	2.46e-06	9.04e-05	CbGpPWpGaD
Etoposide—TOP2A—Cell Cycle—TP53—urinary bladder cancer	2.46e-06	9.04e-05	CbGpPWpGaD
Etoposide—ABCC3—Metabolism—MTHFR—urinary bladder cancer	2.46e-06	9.04e-05	CbGpPWpGaD
Etoposide—ABCC1—Disease—ERCC2—urinary bladder cancer	2.45e-06	9e-05	CbGpPWpGaD
Etoposide—CYP2C8—Metabolism—NAT2—urinary bladder cancer	2.41e-06	8.86e-05	CbGpPWpGaD
Etoposide—CYP2E1—Metabolism—RRM2—urinary bladder cancer	2.41e-06	8.85e-05	CbGpPWpGaD
Etoposide—ABCC1—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	2.41e-06	8.85e-05	CbGpPWpGaD
Etoposide—PTGS1—Metabolism—NQO1—urinary bladder cancer	2.41e-06	8.84e-05	CbGpPWpGaD
Etoposide—CYP3A5—Metabolism—RRM2—urinary bladder cancer	2.41e-06	8.83e-05	CbGpPWpGaD
Etoposide—PTGS2—Disease—JAG1—urinary bladder cancer	2.4e-06	8.82e-05	CbGpPWpGaD
Etoposide—CYP1A2—Metabolism—SLC19A1—urinary bladder cancer	2.38e-06	8.75e-05	CbGpPWpGaD
Etoposide—ABCC1—Metabolism—GSTP1—urinary bladder cancer	2.38e-06	8.72e-05	CbGpPWpGaD
Etoposide—PTGS2—Metabolism—HPGDS—urinary bladder cancer	2.37e-06	8.7e-05	CbGpPWpGaD
Etoposide—PTGS2—Metabolism—ENO2—urinary bladder cancer	2.37e-06	8.7e-05	CbGpPWpGaD
Etoposide—CYP3A4—Metabolism—GSTO2—urinary bladder cancer	2.37e-06	8.68e-05	CbGpPWpGaD
Etoposide—CYP3A4—Metabolism—NAT1—urinary bladder cancer	2.37e-06	8.68e-05	CbGpPWpGaD
Etoposide—PTGS2—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	2.36e-06	8.65e-05	CbGpPWpGaD
Etoposide—PTGS1—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	2.34e-06	8.58e-05	CbGpPWpGaD
Etoposide—ABCB1—Metabolism—TYMP—urinary bladder cancer	2.33e-06	8.53e-05	CbGpPWpGaD
Etoposide—CYP1A2—Metabolism—PRSS3—urinary bladder cancer	2.32e-06	8.52e-05	CbGpPWpGaD
Etoposide—ABCC1—Disease—MTHFR—urinary bladder cancer	2.3e-06	8.46e-05	CbGpPWpGaD
Etoposide—PTGS2—Metabolism—GSTT1—urinary bladder cancer	2.3e-06	8.44e-05	CbGpPWpGaD
Etoposide—ABCC1—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	2.3e-06	8.44e-05	CbGpPWpGaD
Etoposide—ABCC1—Disease—TERT—urinary bladder cancer	2.3e-06	8.43e-05	CbGpPWpGaD
Etoposide—UGT1A1—Metabolism—TYMS—urinary bladder cancer	2.29e-06	8.41e-05	CbGpPWpGaD
Etoposide—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—urinary bladder cancer	2.28e-06	8.38e-05	CbGpPWpGaD
Etoposide—PTGS2—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	2.27e-06	8.31e-05	CbGpPWpGaD
Etoposide—UGT1A1—Metabolism—GSTM1—urinary bladder cancer	2.26e-06	8.31e-05	CbGpPWpGaD
Etoposide—UGT1A1—Metabolism—NCOR1—urinary bladder cancer	2.26e-06	8.31e-05	CbGpPWpGaD
Etoposide—CYP2E1—Metabolism—HPGDS—urinary bladder cancer	2.23e-06	8.19e-05	CbGpPWpGaD
Etoposide—CYP2E1—Metabolism—ENO2—urinary bladder cancer	2.23e-06	8.19e-05	CbGpPWpGaD
Etoposide—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—urinary bladder cancer	2.23e-06	8.19e-05	CbGpPWpGaD
Etoposide—CYP3A5—Metabolism—ENO2—urinary bladder cancer	2.23e-06	8.18e-05	CbGpPWpGaD
Etoposide—CYP3A5—Metabolism—HPGDS—urinary bladder cancer	2.23e-06	8.18e-05	CbGpPWpGaD
Etoposide—GSTP1—Metabolism—PTEN—urinary bladder cancer	2.22e-06	8.14e-05	CbGpPWpGaD
Etoposide—ABCC1—Metabolism—TYMS—urinary bladder cancer	2.21e-06	8.11e-05	CbGpPWpGaD
Etoposide—ABCC1—Metabolism—GSTM1—urinary bladder cancer	2.18e-06	8.01e-05	CbGpPWpGaD
Etoposide—ABCC1—Metabolism—NCOR1—urinary bladder cancer	2.18e-06	8.01e-05	CbGpPWpGaD
Etoposide—UGT1A1—Metabolism—GPX1—urinary bladder cancer	2.17e-06	7.96e-05	CbGpPWpGaD
Etoposide—CYP2E1—Metabolism—GSTT1—urinary bladder cancer	2.17e-06	7.95e-05	CbGpPWpGaD
Etoposide—CYP3A4—Metabolism—UGT2B7—urinary bladder cancer	2.16e-06	7.94e-05	CbGpPWpGaD
Etoposide—CYP3A5—Metabolism—GSTT1—urinary bladder cancer	2.16e-06	7.93e-05	CbGpPWpGaD
Etoposide—UGT1A1—Metabolism—ERCC2—urinary bladder cancer	2.13e-06	7.81e-05	CbGpPWpGaD
Etoposide—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—urinary bladder cancer	2.13e-06	7.8e-05	CbGpPWpGaD
Etoposide—GSTP1—Metabolism—EP300—urinary bladder cancer	2.12e-06	7.76e-05	CbGpPWpGaD
Etoposide—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—urinary bladder cancer	2.11e-06	7.74e-05	CbGpPWpGaD
Etoposide—ABCC1—Disease—FGFR3—urinary bladder cancer	2.11e-06	7.74e-05	CbGpPWpGaD
Etoposide—ABCB1—Metabolism—NAT2—urinary bladder cancer	2.1e-06	7.72e-05	CbGpPWpGaD
Etoposide—ABCC1—Metabolism—GPX1—urinary bladder cancer	2.09e-06	7.67e-05	CbGpPWpGaD
Etoposide—ABCG2—Metabolism—GSTP1—urinary bladder cancer	2.09e-06	7.67e-05	CbGpPWpGaD
Etoposide—CYP2C8—Metabolism—RRM2—urinary bladder cancer	2.08e-06	7.65e-05	CbGpPWpGaD
Etoposide—ABCC1—Metabolism—ERCC2—urinary bladder cancer	2.05e-06	7.53e-05	CbGpPWpGaD
Etoposide—PTGS1—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	2.04e-06	7.48e-05	CbGpPWpGaD
Etoposide—PTGS1—Metabolism—GSTP1—urinary bladder cancer	2.01e-06	7.37e-05	CbGpPWpGaD
Etoposide—UGT1A1—Metabolism—MTHFR—urinary bladder cancer	2e-06	7.34e-05	CbGpPWpGaD
Etoposide—ABCC3—Metabolism—PPARG—urinary bladder cancer	2e-06	7.33e-05	CbGpPWpGaD
Etoposide—CYP3A4—Metabolism—CYP4B1—urinary bladder cancer	1.95e-06	7.15e-05	CbGpPWpGaD
Etoposide—ABCG2—Metabolism—TYMS—urinary bladder cancer	1.94e-06	7.13e-05	CbGpPWpGaD
Etoposide—PTGS1—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	1.94e-06	7.13e-05	CbGpPWpGaD
Etoposide—CYP2C8—Metabolism—ENO2—urinary bladder cancer	1.93e-06	7.08e-05	CbGpPWpGaD
Etoposide—CYP2C8—Metabolism—HPGDS—urinary bladder cancer	1.93e-06	7.08e-05	CbGpPWpGaD
Etoposide—ABCC1—Metabolism—MTHFR—urinary bladder cancer	1.93e-06	7.08e-05	CbGpPWpGaD
Etoposide—ABCG2—Metabolism—GSTM1—urinary bladder cancer	1.92e-06	7.05e-05	CbGpPWpGaD
Etoposide—ABCG2—Metabolism—NCOR1—urinary bladder cancer	1.92e-06	7.05e-05	CbGpPWpGaD
Etoposide—CYP2C8—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	1.92e-06	7.04e-05	CbGpPWpGaD
Etoposide—ABCC3—Metabolism—CREBBP—urinary bladder cancer	1.92e-06	7.04e-05	CbGpPWpGaD
Etoposide—PTGS2—Metabolism—NQO1—urinary bladder cancer	1.91e-06	7.02e-05	CbGpPWpGaD
Etoposide—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—urinary bladder cancer	1.87e-06	6.88e-05	CbGpPWpGaD
Etoposide—CYP2C8—Metabolism—GSTT1—urinary bladder cancer	1.87e-06	6.87e-05	CbGpPWpGaD
Etoposide—PTGS1—Metabolism—TYMS—urinary bladder cancer	1.87e-06	6.85e-05	CbGpPWpGaD
Etoposide—CYP1A2—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	1.86e-06	6.83e-05	CbGpPWpGaD
Etoposide—CYP1A2—Metabolism—TYMP—urinary bladder cancer	1.86e-06	6.81e-05	CbGpPWpGaD
Etoposide—PTGS1—Metabolism—GSTM1—urinary bladder cancer	1.85e-06	6.77e-05	CbGpPWpGaD
Etoposide—PTGS1—Metabolism—NCOR1—urinary bladder cancer	1.85e-06	6.77e-05	CbGpPWpGaD
Etoposide—CYP2C8—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	1.84e-06	6.76e-05	CbGpPWpGaD
Etoposide—ABCG2—Metabolism—GPX1—urinary bladder cancer	1.84e-06	6.75e-05	CbGpPWpGaD
Etoposide—CYP3A4—Metabolism—SLC19A1—urinary bladder cancer	1.84e-06	6.75e-05	CbGpPWpGaD
Etoposide—ABCB1—Metabolism—RRM2—urinary bladder cancer	1.82e-06	6.66e-05	CbGpPWpGaD
Etoposide—ABCG2—Metabolism—ERCC2—urinary bladder cancer	1.81e-06	6.63e-05	CbGpPWpGaD
Etoposide—CYP2E1—Metabolism—NQO1—urinary bladder cancer	1.8e-06	6.6e-05	CbGpPWpGaD
Etoposide—CYP3A5—Metabolism—NQO1—urinary bladder cancer	1.8e-06	6.59e-05	CbGpPWpGaD
Etoposide—ABCC1—Disease—CREBBP—urinary bladder cancer	1.8e-06	6.59e-05	CbGpPWpGaD
Etoposide—CYP3A4—Metabolism—PRSS3—urinary bladder cancer	1.79e-06	6.58e-05	CbGpPWpGaD
Etoposide—CYP1A2—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	1.78e-06	6.54e-05	CbGpPWpGaD
Etoposide—PTGS1—Metabolism—GPX1—urinary bladder cancer	1.77e-06	6.49e-05	CbGpPWpGaD
Etoposide—PTGS2—Disease—NCOR1—urinary bladder cancer	1.75e-06	6.42e-05	CbGpPWpGaD
Etoposide—PTGS1—Metabolism—ERCC2—urinary bladder cancer	1.74e-06	6.37e-05	CbGpPWpGaD
Etoposide—ABCG2—Metabolism—MTHFR—urinary bladder cancer	1.7e-06	6.23e-05	CbGpPWpGaD
Etoposide—ABCB1—Metabolism—HPGDS—urinary bladder cancer	1.68e-06	6.17e-05	CbGpPWpGaD
Etoposide—ABCB1—Metabolism—ENO2—urinary bladder cancer	1.68e-06	6.17e-05	CbGpPWpGaD
Etoposide—CYP1A2—Metabolism—NAT2—urinary bladder cancer	1.68e-06	6.16e-05	CbGpPWpGaD
Etoposide—PTGS2—Disease—ERCC2—urinary bladder cancer	1.65e-06	6.04e-05	CbGpPWpGaD
Etoposide—PTGS1—Metabolism—MTHFR—urinary bladder cancer	1.63e-06	5.99e-05	CbGpPWpGaD
Etoposide—ABCB1—Metabolism—GSTT1—urinary bladder cancer	1.63e-06	5.98e-05	CbGpPWpGaD
Etoposide—ABCC1—Disease—RHOA—urinary bladder cancer	1.62e-06	5.96e-05	CbGpPWpGaD
Etoposide—UGT1A1—Metabolism—PPARG—urinary bladder cancer	1.62e-06	5.96e-05	CbGpPWpGaD
Etoposide—PTGS2—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	1.62e-06	5.94e-05	CbGpPWpGaD
Etoposide—PTGS2—Metabolism—GSTP1—urinary bladder cancer	1.6e-06	5.85e-05	CbGpPWpGaD
Etoposide—ABCC3—Metabolism—PTGS2—urinary bladder cancer	1.57e-06	5.76e-05	CbGpPWpGaD
Etoposide—ABCC1—Metabolism—PPARG—urinary bladder cancer	1.57e-06	5.74e-05	CbGpPWpGaD
Etoposide—UGT1A1—Metabolism—CREBBP—urinary bladder cancer	1.56e-06	5.72e-05	CbGpPWpGaD
Etoposide—CYP2C8—Metabolism—NQO1—urinary bladder cancer	1.56e-06	5.71e-05	CbGpPWpGaD
Etoposide—PTGS2—Disease—MTHFR—urinary bladder cancer	1.55e-06	5.67e-05	CbGpPWpGaD
Etoposide—PTGS2—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	1.54e-06	5.66e-05	CbGpPWpGaD
Etoposide—PTGS2—Disease—TERT—urinary bladder cancer	1.54e-06	5.66e-05	CbGpPWpGaD
Etoposide—ABCB1—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	1.53e-06	5.6e-05	CbGpPWpGaD
Etoposide—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	1.51e-06	5.54e-05	CbGpPWpGaD
Etoposide—ABCC1—Metabolism—CREBBP—urinary bladder cancer	1.5e-06	5.52e-05	CbGpPWpGaD
Etoposide—ABCC1—Disease—ERBB2—urinary bladder cancer	1.5e-06	5.52e-05	CbGpPWpGaD
Etoposide—CYP2E1—Metabolism—GSTP1—urinary bladder cancer	1.5e-06	5.51e-05	CbGpPWpGaD
Etoposide—CYP3A5—Metabolism—GSTP1—urinary bladder cancer	1.5e-06	5.5e-05	CbGpPWpGaD
Etoposide—PTGS2—Metabolism—TYMS—urinary bladder cancer	1.48e-06	5.44e-05	CbGpPWpGaD
Etoposide—ABCC1—Disease—PTGS2—urinary bladder cancer	1.47e-06	5.39e-05	CbGpPWpGaD
Etoposide—PTGS2—Metabolism—NCOR1—urinary bladder cancer	1.47e-06	5.38e-05	CbGpPWpGaD
Etoposide—PTGS2—Metabolism—GSTM1—urinary bladder cancer	1.47e-06	5.38e-05	CbGpPWpGaD
Etoposide—CYP1A2—Metabolism—RRM2—urinary bladder cancer	1.45e-06	5.32e-05	CbGpPWpGaD
Etoposide—CYP3A4—Metabolism—TYMP—urinary bladder cancer	1.43e-06	5.26e-05	CbGpPWpGaD
Etoposide—PTGS2—Disease—FGFR3—urinary bladder cancer	1.42e-06	5.19e-05	CbGpPWpGaD
Etoposide—PTGS2—Metabolism—GPX1—urinary bladder cancer	1.4e-06	5.15e-05	CbGpPWpGaD
Etoposide—CYP2E1—Metabolism—TYMS—urinary bladder cancer	1.4e-06	5.12e-05	CbGpPWpGaD
Etoposide—CYP3A5—Metabolism—TYMS—urinary bladder cancer	1.39e-06	5.11e-05	CbGpPWpGaD
Etoposide—CYP2E1—Metabolism—GSTM1—urinary bladder cancer	1.38e-06	5.06e-05	CbGpPWpGaD
Etoposide—CYP2E1—Metabolism—NCOR1—urinary bladder cancer	1.38e-06	5.06e-05	CbGpPWpGaD
Etoposide—PTGS2—Metabolism—ERCC2—urinary bladder cancer	1.38e-06	5.06e-05	CbGpPWpGaD
Etoposide—ABCG2—Metabolism—PPARG—urinary bladder cancer	1.38e-06	5.05e-05	CbGpPWpGaD
Etoposide—CYP3A5—Metabolism—NCOR1—urinary bladder cancer	1.38e-06	5.05e-05	CbGpPWpGaD
Etoposide—CYP3A5—Metabolism—GSTM1—urinary bladder cancer	1.38e-06	5.05e-05	CbGpPWpGaD
Etoposide—ABCC3—Metabolism—PTEN—urinary bladder cancer	1.37e-06	5.03e-05	CbGpPWpGaD
Etoposide—ABCB1—Metabolism—NQO1—urinary bladder cancer	1.36e-06	4.97e-05	CbGpPWpGaD
Etoposide—CYP1A2—Metabolism—ENO2—urinary bladder cancer	1.34e-06	4.93e-05	CbGpPWpGaD
Etoposide—CYP1A2—Metabolism—HPGDS—urinary bladder cancer	1.34e-06	4.93e-05	CbGpPWpGaD
Etoposide—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	1.33e-06	4.9e-05	CbGpPWpGaD
Etoposide—PTGS1—Metabolism—PPARG—urinary bladder cancer	1.32e-06	4.85e-05	CbGpPWpGaD
Etoposide—ABCG2—Metabolism—CREBBP—urinary bladder cancer	1.32e-06	4.85e-05	CbGpPWpGaD
Etoposide—CYP2E1—Metabolism—GPX1—urinary bladder cancer	1.32e-06	4.85e-05	CbGpPWpGaD
Etoposide—CYP3A5—Metabolism—GPX1—urinary bladder cancer	1.32e-06	4.84e-05	CbGpPWpGaD
Etoposide—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	1.32e-06	4.83e-05	CbGpPWpGaD
Etoposide—ABCC3—Metabolism—EP300—urinary bladder cancer	1.31e-06	4.79e-05	CbGpPWpGaD
Etoposide—CYP1A2—Metabolism—GSTT1—urinary bladder cancer	1.3e-06	4.78e-05	CbGpPWpGaD
Etoposide—CYP2C8—Metabolism—GSTP1—urinary bladder cancer	1.3e-06	4.76e-05	CbGpPWpGaD
Etoposide—CYP2E1—Metabolism—ERCC2—urinary bladder cancer	1.3e-06	4.76e-05	CbGpPWpGaD
Etoposide—CYP3A4—Metabolism—NAT2—urinary bladder cancer	1.3e-06	4.76e-05	CbGpPWpGaD
Etoposide—PTGS2—Metabolism—MTHFR—urinary bladder cancer	1.3e-06	4.75e-05	CbGpPWpGaD
Etoposide—CYP3A5—Metabolism—ERCC2—urinary bladder cancer	1.29e-06	4.75e-05	CbGpPWpGaD
Etoposide—ABCC1—Disease—CDKN1A—urinary bladder cancer	1.29e-06	4.71e-05	CbGpPWpGaD
Etoposide—CYP1A2—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	1.28e-06	4.7e-05	CbGpPWpGaD
Etoposide—ABCC1—Disease—PTEN—urinary bladder cancer	1.28e-06	4.7e-05	CbGpPWpGaD
Etoposide—UGT1A1—Metabolism—PTGS2—urinary bladder cancer	1.28e-06	4.68e-05	CbGpPWpGaD
Etoposide—PTGS1—Metabolism—CREBBP—urinary bladder cancer	1.27e-06	4.66e-05	CbGpPWpGaD
Etoposide—CYP2C8—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	1.26e-06	4.61e-05	CbGpPWpGaD
Etoposide—ABCC1—Metabolism—PTGS2—urinary bladder cancer	1.23e-06	4.52e-05	CbGpPWpGaD
Etoposide—ABCC1—Disease—EP300—urinary bladder cancer	1.22e-06	4.49e-05	CbGpPWpGaD
Etoposide—CYP2E1—Metabolism—MTHFR—urinary bladder cancer	1.22e-06	4.47e-05	CbGpPWpGaD
Etoposide—CYP3A5—Metabolism—MTHFR—urinary bladder cancer	1.22e-06	4.46e-05	CbGpPWpGaD
Etoposide—CYP2C8—Metabolism—TYMS—urinary bladder cancer	1.21e-06	4.43e-05	CbGpPWpGaD
Etoposide—PTGS2—Disease—CREBBP—urinary bladder cancer	1.2e-06	4.42e-05	CbGpPWpGaD
Etoposide—CYP2C8—Metabolism—GSTM1—urinary bladder cancer	1.19e-06	4.38e-05	CbGpPWpGaD
Etoposide—CYP2C8—Metabolism—NCOR1—urinary bladder cancer	1.19e-06	4.38e-05	CbGpPWpGaD
Etoposide—ABCC1—Disease—SRC—urinary bladder cancer	1.19e-06	4.36e-05	CbGpPWpGaD
Etoposide—CYP2C8—Metabolism—GPX1—urinary bladder cancer	1.14e-06	4.19e-05	CbGpPWpGaD
Etoposide—ABCB1—Metabolism—GSTP1—urinary bladder cancer	1.13e-06	4.15e-05	CbGpPWpGaD
Etoposide—CYP2C8—Metabolism—ERCC2—urinary bladder cancer	1.12e-06	4.11e-05	CbGpPWpGaD
Etoposide—CYP3A4—Metabolism—RRM2—urinary bladder cancer	1.12e-06	4.1e-05	CbGpPWpGaD
Etoposide—UGT1A1—Metabolism—PTEN—urinary bladder cancer	1.11e-06	4.09e-05	CbGpPWpGaD
Etoposide—PTGS2—Disease—RHOA—urinary bladder cancer	1.09e-06	4e-05	CbGpPWpGaD
Etoposide—ABCG2—Metabolism—PTGS2—urinary bladder cancer	1.08e-06	3.97e-05	CbGpPWpGaD
Etoposide—CYP1A2—Metabolism—NQO1—urinary bladder cancer	1.08e-06	3.97e-05	CbGpPWpGaD
Etoposide—ABCC1—Metabolism—PTEN—urinary bladder cancer	1.07e-06	3.94e-05	CbGpPWpGaD
Etoposide—ABCC1—Disease—MYC—urinary bladder cancer	1.07e-06	3.91e-05	CbGpPWpGaD
Etoposide—UGT1A1—Metabolism—EP300—urinary bladder cancer	1.06e-06	3.9e-05	CbGpPWpGaD
Etoposide—CYP2C8—Metabolism—MTHFR—urinary bladder cancer	1.05e-06	3.87e-05	CbGpPWpGaD
Etoposide—ABCB1—Metabolism—TYMS—urinary bladder cancer	1.05e-06	3.86e-05	CbGpPWpGaD
Etoposide—PTGS2—Metabolism—PPARG—urinary bladder cancer	1.05e-06	3.85e-05	CbGpPWpGaD
Etoposide—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	1.05e-06	3.85e-05	CbGpPWpGaD
Etoposide—ABCC1—Disease—EGFR—urinary bladder cancer	1.04e-06	3.82e-05	CbGpPWpGaD
Etoposide—PTGS1—Metabolism—PTGS2—urinary bladder cancer	1.04e-06	3.82e-05	CbGpPWpGaD
Etoposide—ABCB1—Metabolism—NCOR1—urinary bladder cancer	1.04e-06	3.81e-05	CbGpPWpGaD
Etoposide—ABCB1—Metabolism—GSTM1—urinary bladder cancer	1.04e-06	3.81e-05	CbGpPWpGaD
Etoposide—CYP3A4—Metabolism—HPGDS—urinary bladder cancer	1.04e-06	3.8e-05	CbGpPWpGaD
Etoposide—CYP3A4—Metabolism—ENO2—urinary bladder cancer	1.04e-06	3.8e-05	CbGpPWpGaD
Etoposide—ABCC1—Metabolism—EP300—urinary bladder cancer	1.02e-06	3.76e-05	CbGpPWpGaD
Etoposide—PTGS2—Metabolism—CREBBP—urinary bladder cancer	1.01e-06	3.7e-05	CbGpPWpGaD
Etoposide—PTGS2—Disease—ERBB2—urinary bladder cancer	1.01e-06	3.7e-05	CbGpPWpGaD
Etoposide—CYP3A4—Metabolism—GSTT1—urinary bladder cancer	1e-06	3.69e-05	CbGpPWpGaD
Etoposide—ABCB1—Metabolism—GPX1—urinary bladder cancer	9.95e-07	3.65e-05	CbGpPWpGaD
Etoposide—CYP2E1—Metabolism—PPARG—urinary bladder cancer	9.89e-07	3.63e-05	CbGpPWpGaD
Etoposide—CYP3A5—Metabolism—PPARG—urinary bladder cancer	9.87e-07	3.62e-05	CbGpPWpGaD
Etoposide—ABCC1—Disease—KRAS—urinary bladder cancer	9.85e-07	3.61e-05	CbGpPWpGaD
Etoposide—ABCB1—Metabolism—ERCC2—urinary bladder cancer	9.77e-07	3.58e-05	CbGpPWpGaD
Etoposide—CYP2E1—Metabolism—CREBBP—urinary bladder cancer	9.5e-07	3.49e-05	CbGpPWpGaD
Etoposide—CYP3A5—Metabolism—CREBBP—urinary bladder cancer	9.48e-07	3.48e-05	CbGpPWpGaD
Etoposide—ABCG2—Metabolism—PTEN—urinary bladder cancer	9.45e-07	3.47e-05	CbGpPWpGaD
Etoposide—ABCB1—Metabolism—MTHFR—urinary bladder cancer	9.18e-07	3.37e-05	CbGpPWpGaD
Etoposide—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	9.16e-07	3.36e-05	CbGpPWpGaD
Etoposide—PTGS1—Metabolism—PTEN—urinary bladder cancer	9.08e-07	3.33e-05	CbGpPWpGaD
Etoposide—CYP1A2—Metabolism—GSTP1—urinary bladder cancer	9.03e-07	3.31e-05	CbGpPWpGaD
Etoposide—ABCG2—Metabolism—EP300—urinary bladder cancer	9.01e-07	3.31e-05	CbGpPWpGaD
Etoposide—CYP1A2—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	8.73e-07	3.2e-05	CbGpPWpGaD
Etoposide—PTGS1—Metabolism—EP300—urinary bladder cancer	8.66e-07	3.18e-05	CbGpPWpGaD
Etoposide—PTGS2—Disease—CDKN1A—urinary bladder cancer	8.62e-07	3.16e-05	CbGpPWpGaD
Etoposide—PTGS2—Disease—PTEN—urinary bladder cancer	8.6e-07	3.16e-05	CbGpPWpGaD
Etoposide—CYP2C8—Metabolism—PPARG—urinary bladder cancer	8.55e-07	3.14e-05	CbGpPWpGaD
Etoposide—CYP1A2—Metabolism—TYMS—urinary bladder cancer	8.39e-07	3.08e-05	CbGpPWpGaD
Etoposide—ABCC1—Disease—HRAS—urinary bladder cancer	8.37e-07	3.07e-05	CbGpPWpGaD
Etoposide—CYP3A4—Metabolism—NQO1—urinary bladder cancer	8.35e-07	3.06e-05	CbGpPWpGaD
Etoposide—CYP1A2—Metabolism—NCOR1—urinary bladder cancer	8.29e-07	3.04e-05	CbGpPWpGaD
Etoposide—CYP1A2—Metabolism—GSTM1—urinary bladder cancer	8.29e-07	3.04e-05	CbGpPWpGaD
Etoposide—CYP2C8—Metabolism—CREBBP—urinary bladder cancer	8.21e-07	3.01e-05	CbGpPWpGaD
Etoposide—PTGS2—Disease—EP300—urinary bladder cancer	8.21e-07	3.01e-05	CbGpPWpGaD
Etoposide—PTGS2—Disease—SRC—urinary bladder cancer	7.98e-07	2.93e-05	CbGpPWpGaD
Etoposide—CYP1A2—Metabolism—GPX1—urinary bladder cancer	7.94e-07	2.91e-05	CbGpPWpGaD
Etoposide—CYP1A2—Metabolism—ERCC2—urinary bladder cancer	7.8e-07	2.86e-05	CbGpPWpGaD
Etoposide—CYP2E1—Metabolism—PTGS2—urinary bladder cancer	7.78e-07	2.85e-05	CbGpPWpGaD
Etoposide—CYP3A5—Metabolism—PTGS2—urinary bladder cancer	7.76e-07	2.85e-05	CbGpPWpGaD
Etoposide—ABCB1—Metabolism—PPARG—urinary bladder cancer	7.45e-07	2.73e-05	CbGpPWpGaD
Etoposide—CYP1A2—Metabolism—MTHFR—urinary bladder cancer	7.33e-07	2.69e-05	CbGpPWpGaD
Etoposide—PTGS2—Metabolism—PTEN—urinary bladder cancer	7.21e-07	2.64e-05	CbGpPWpGaD
Etoposide—ABCB1—Metabolism—CREBBP—urinary bladder cancer	7.15e-07	2.62e-05	CbGpPWpGaD
Etoposide—PTGS2—Disease—MYC—urinary bladder cancer	7.15e-07	2.62e-05	CbGpPWpGaD
Etoposide—PTGS2—Disease—EGFR—urinary bladder cancer	6.99e-07	2.57e-05	CbGpPWpGaD
Etoposide—CYP3A4—Metabolism—GSTP1—urinary bladder cancer	6.97e-07	2.56e-05	CbGpPWpGaD
Etoposide—PTGS2—Metabolism—EP300—urinary bladder cancer	6.87e-07	2.52e-05	CbGpPWpGaD
Etoposide—CYP2E1—Metabolism—PTEN—urinary bladder cancer	6.78e-07	2.49e-05	CbGpPWpGaD
Etoposide—CYP3A5—Metabolism—PTEN—urinary bladder cancer	6.77e-07	2.48e-05	CbGpPWpGaD
Etoposide—CYP2C8—Metabolism—PTGS2—urinary bladder cancer	6.72e-07	2.47e-05	CbGpPWpGaD
Etoposide—PTGS2—Disease—KRAS—urinary bladder cancer	6.61e-07	2.42e-05	CbGpPWpGaD
Etoposide—CYP3A4—Metabolism—TYMS—urinary bladder cancer	6.48e-07	2.38e-05	CbGpPWpGaD
Etoposide—CYP2E1—Metabolism—EP300—urinary bladder cancer	6.47e-07	2.37e-05	CbGpPWpGaD
Etoposide—CYP3A5—Metabolism—EP300—urinary bladder cancer	6.46e-07	2.37e-05	CbGpPWpGaD
Etoposide—CYP3A4—Metabolism—NCOR1—urinary bladder cancer	6.4e-07	2.35e-05	CbGpPWpGaD
Etoposide—CYP3A4—Metabolism—GSTM1—urinary bladder cancer	6.4e-07	2.35e-05	CbGpPWpGaD
Etoposide—CYP3A4—Metabolism—GPX1—urinary bladder cancer	6.13e-07	2.25e-05	CbGpPWpGaD
Etoposide—CYP3A4—Metabolism—ERCC2—urinary bladder cancer	6.02e-07	2.21e-05	CbGpPWpGaD
Etoposide—CYP1A2—Metabolism—PPARG—urinary bladder cancer	5.94e-07	2.18e-05	CbGpPWpGaD
Etoposide—CYP2C8—Metabolism—PTEN—urinary bladder cancer	5.86e-07	2.15e-05	CbGpPWpGaD
Etoposide—ABCB1—Metabolism—PTGS2—urinary bladder cancer	5.86e-07	2.15e-05	CbGpPWpGaD
Etoposide—CYP1A2—Metabolism—CREBBP—urinary bladder cancer	5.71e-07	2.1e-05	CbGpPWpGaD
Etoposide—CYP3A4—Metabolism—MTHFR—urinary bladder cancer	5.66e-07	2.08e-05	CbGpPWpGaD
Etoposide—PTGS2—Disease—HRAS—urinary bladder cancer	5.62e-07	2.06e-05	CbGpPWpGaD
Etoposide—CYP2C8—Metabolism—EP300—urinary bladder cancer	5.59e-07	2.05e-05	CbGpPWpGaD
Etoposide—ABCB1—Metabolism—PTEN—urinary bladder cancer	5.11e-07	1.87e-05	CbGpPWpGaD
Etoposide—ABCB1—Metabolism—EP300—urinary bladder cancer	4.87e-07	1.79e-05	CbGpPWpGaD
Etoposide—CYP1A2—Metabolism—PTGS2—urinary bladder cancer	4.68e-07	1.72e-05	CbGpPWpGaD
Etoposide—CYP3A4—Metabolism—PPARG—urinary bladder cancer	4.59e-07	1.68e-05	CbGpPWpGaD
Etoposide—CYP3A4—Metabolism—CREBBP—urinary bladder cancer	4.41e-07	1.62e-05	CbGpPWpGaD
Etoposide—CYP1A2—Metabolism—PTEN—urinary bladder cancer	4.08e-07	1.5e-05	CbGpPWpGaD
Etoposide—CYP1A2—Metabolism—EP300—urinary bladder cancer	3.89e-07	1.43e-05	CbGpPWpGaD
Etoposide—CYP3A4—Metabolism—PTGS2—urinary bladder cancer	3.61e-07	1.32e-05	CbGpPWpGaD
Etoposide—CYP3A4—Metabolism—PTEN—urinary bladder cancer	3.15e-07	1.15e-05	CbGpPWpGaD
Etoposide—CYP3A4—Metabolism—EP300—urinary bladder cancer	3e-07	1.1e-05	CbGpPWpGaD
